Common Analgesic Gas Enhances Blood-Brain Barrier Opening for Brain Therapy
A new study reveals that nitrous oxide, a common analgesic, can safely enhance the opening of the blood-brain barrier, improving targeted delivery of gene therapy for neurological diseases.
Researchers at UT Southwestern Medical Center have discovered that nitrous oxide, a widely used analgesic gas, can temporarily open the blood-brain barrier (BBB), facilitating targeted delivery of gene therapy into the brain. In their recent study, published in Gene Therapy, the team demonstrated that breathing nitrous oxide during focused ultrasound (FUS) procedures significantly lowers the necessary microbubble concentrations and ultrasound pressures to achieve BBB opening, thereby reducing potential tissue injury.
The blood-brain barrier is an essential structural feature that protects the brain from harmful substances in the blood but also poses a challenge by blocking therapeutic agents from entering the brain tissue. Traditional methods to open the BBB involve microbubbles combined with FUS, which require higher doses and pressures, risking damage to surrounding brain tissue. The innovative approach tested in this study utilizes nitrous oxide to amplify microbubble activity, allowing for effective BBB opening at substantially reduced microbubble levels and FUS pressures.
In experiments with mouse models, scientists observed that using nitrous oxide required up to 1,000 times lower microbubble concentration compared to air, significantly minimizing risks associated with the procedure. The study verified this method by delivering a gene that produces a visible green fluorescence in the brain, confirming enhanced gene uptake and expression. These promising results suggest that this technique could pave the way for safer, more efficient brain drug delivery systems.
The researchers are now preparing to advance this approach into clinical trials, aiming to improve treatment options for neurological conditions such as Alzheimer's disease, multiple sclerosis, and brain tumors. This breakthrough could represent a significant step forward in non-invasive brain therapy, offering hope for more effective management of serious brain disorders.
Source: https://medicalxpress.com/news/2025-05-common-analgesic-gas-aids-blood.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Study Finds COVID-19 School Closures in the US Were Not Cost-Effective Compared to Other Interventions
A new study reveals that COVID-19 school closures in the US were not cost-effective, highlighting the effectiveness of mask mandates, testing, and contact tracing as better alternatives for pandemic control.
Using Air Purifiers Can Lower Heart Risks for Those Exposed to Traffic Pollution
Using portable HEPA air purifiers may significantly reduce blood pressure in adults exposed to traffic-related air pollution, potentially lowering cardiovascular risks—a promising low-cost intervention for vulnerable populations.
Breakthrough in Cancer Precision Therapy: Identifying Patients Who Benefit from Bexmarilimab
A new study unveils how bexmarilimab activates the immune system against cancer and introduces a gene signature for selective patient treatment, advancing personalized immunotherapy.
2025 Clinical Practice Guidelines for Hematopoietic Cell Transplantation and CAR-T Therapy
The EBMT has released updated clinical guidelines for hematopoietic cell transplantation and CAR-T therapies in 2025, emphasizing standardization, innovation, and personalized treatment strategies to improve patient outcomes across hematological and immune disorders.